85547-56-4
中文名稱
磷酸哌喹
英文名稱
4,4'-(1,3-Propanediyldi-4,1-piperazinediyl)bis(7-chloroquinoline) phosphate
CAS
85547-56-4
分子式
C29H32Cl2N6.H3PO4
分子量
633.51
MOL 文件
85547-56-4.mol
更新日期
2026/07/10 13:10:23
85547-56-4 結(jié)構(gòu)式
基本信息
中文別名
磷酸喹哌磷酸哌喹
哌喹磷酸鹽
1,3-雙[4-(7-氯-喹啉-4-基)哌嗪-1-基]丙烷磷酸鹽
英文別名
85547-56-4PIPERAQUINE PHOSPHATE
antimalarial drugs PIPERAQUINE PHOSPHATE
2-(9-methyldecyl)-5-(4-methylpentyl)benzene-1,3-diol
4,4'-(1,3-Propanediyldi-4,1-piperazinediyl)bis(7-chloroquinoline)
4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloroquinoline) phosphate
Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-, phosphate
4,4'-(1,3-Propanediyldi-4,1-piperazinediyl)bis(7-chloroquinoline) phosphate USP/EP/BP
所屬類別
原料藥：抗瘧藥物理化學(xué)性質(zhì)
儲存條件-20°C儲存
溶解度DMSO: Insoluble;
形態(tài)Solid
顏色Off-white to light yellow
水溶解性Water: 2 mg/mL (3.16 mM)
InChIKeyKATNPMSTHHZOTK-UHFFFAOYSA-N
SMILESC(N1CCN(C2=C3C(=NC=C2)C=C(Cl)C=C3)CC1)CCN1CCN(C2=C3C(=NC=C2)C=C(Cl)C=C3)CC1.P(O)(O)(O)=O
磷酸哌喹價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/07/06 | S5355 | 磷酸哌喹 Piperaquine phosphate | 85547-56-4 | 25mg | 794.54元 |
| 2026/06/05 | HY-B1896AR | 磷酸哌喹 Piperaquine phosphate (Standard) | 85547-56-4 | 5 mg | 500元 |
| 2026/06/05 | HY-B1896AR | 磷酸哌喹 Piperaquine phosphate (Standard) | 85547-56-4 | 10 mg | 800元 |
常見問題列表
生物活性
Piperaquine phosphate 是一種雙喹啉抗瘧藥，可以與青蒿素聯(lián)用于抗瘧研究。體內(nèi)研究
Piperaquine (10-90 mg/kg; a single i.p.) decreases parasitemia at all of the doses tested in mice.
Piperaquine (90 mg/kg; a single i.p.) exhibits the t
1/2
, apparent clearance, and apparent volume of distribution 17.8 days, 33.5 mg?h/L, 1.55 L/h/kg, and 956 L/kg, respectively, in healthy mice and 16.1 days, 27.3 mg?h/L, 1.9 L/h/kg, and 1,059 L/kg in malaria-infected mice.
| Animal Model: | Male BALB/c mice (7 to 8 weeks) are inoculated with Plasmodium berghei parasites |
| Dosage: | 0, 10, 30, 90 mg/kg |
| Administration: | A single i.p. administration |
| Result: |
The median survival time was 10 days at dose of 10 mg/kg.
The median survival time was 54 days at dose of 30 mg/kg. All mice were active and alert and had stable body weights throughout the course of the study at dose of 90 mg/kg. |
| Animal Model: | Male Swiss mice (6 weeks old) |
| Dosage: | 90 mg/kg (Pharmacokinetic Analysis) |
| Administration: | A single i.p. administration |
| Result: | t 1/2 =17.8 d; AUC=33.5 mg?h/L; apparent clearance=1.55 L/h/kg; apparent volume of distribution=956 L/kg. |